ELMD trades 16.8% above Wall Street's consensus target of $38.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ELMD achieves its forward estimates and maintains a stable P/E multiple of 37.6x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Electromed, Inc. (ELMD) has a Wall Street consensus price target of $38.00, based on estimates from 5 covering analysts. With the stock currently trading at $45.70, this represents a potential downside of -16.8%. The company has a market capitalization of $378M.
Analyst price targets range from a low of $38.00 to a high of $38.00, representing a 0% spread in expectations. The median target of $38.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ELMD trades at a trailing P/E of 53.1x and forward P/E of 37.6x. The forward PEG ratio of 2.92 reflects a premium valuation. Analysts expect EPS to grow +4.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $44.49, with bear and bull scenarios of $28.03 and $58.62 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
INGNInogen, Inc. | $177M | $6.54 | $26.00 | +297.6% | Buy | — | 11 |
LNTHLantheus Holdings, Inc. | $6.7B | $103.41 | $108.50 | +4.9% | Buy | 19.3x | 17 |
LUNGPulmonx Corporation | $65M | $1.53 | — | — | — | — | — |
SPXCSPX Technologies, Inc. | $11.0B | $218.83 | $269.00 | +22.9% | Buy | 27.3x | 12 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
PHGKoninklijke Philips N.V. | $26.9B | $28.23 | — | — | Hold | 18.2x | 22 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
MASIMasimo Corporation | $9.4B | $179.95 | $180.00 | +0.0% | Buy | 32.7x | 23 |
Quick answers to the most common questions about buying ELMD stock.
ELMD's consensus price target is $38, -16.8% below the current price of $45.7. The 5 analysts tracking ELMD see downside risk at present valuations.
ELMD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies -16.8% downside from current levels.
At a forward P/E of 37.5606x, ELMD trades at a premium valuation. The consensus price target of $38 (-16.8% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $38 for ELMD, while the most conservative target is $38. The consensus of $38 represents the median expectation. Our quantitative valuation model projects a bull case target of $59 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ELMD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ELMD stock forecast based on 5 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $38 (bear case) to $38 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $44, with bear/bull scenarios of $28/$59.
Our quantitative valuation model calculates ELMD's fair value at $44 (base case), with a bear case of $28 and bull case of $59. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
ELMD trades at a forward P/E ratio of 37.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 53.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on ELMD, with 0 Sell ratings and a price target of $38 (-16.8% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ELMD analyst price targets range from $38 to $38, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground. Our model's $28-$59 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.